2018, Number 4
<< Back Next >>
Cir Card Mex 2018; 3 (4)
Conservative doses of the solution Histidine- Tryptophan-Ketoglutarate (HTK) for pediatric cardiac surgery with short aortic clamping
Serrano-Gallardo G, Hernández-González R, Jasso-Valenzuela G, Velazco-Rodríguez VM, Salas F
Language: Spanish
References: 15
Page: 103-106
PDF size: 123.09 Kb.
ABSTRACT
The concept of myocardial preservation, preservative
solutions and their doses are still in flux. Cardioplegic
solution of Histidine-Tryptophan Ketoglutarate (HTK)
has proved to be effective in adult as well as pediatric patients
over three decades.
Material and Methods. In 47 children diagnosed with
congenital heart disease, with low and medium surgical
risk we used HTK cardioplegic solution in a single
dose, enough to bring the heart to asystole and cardiac
electrical inactivity during surgical repair. Early post reperfusion
arrhythmias were recorded and its follow-up
to discharge.
Results. Corrective surgical procedure was performed in
all patients, using a cardioplegia dosage of 18.18 ml/kg
for myocardial preservation. Aortic cross-clamping time
was 34.3 minutes in average, and spontaneous defibrillation
was 85.1%. All patients had an uneventful postoperative
course. Hospital discharge was at 5 days after
operation in average.
Conclusions. HTK solution is safe at low doses to maintain
myocardial preservation in pediatric cardiac surgery
with short aortic cross-clamping time.
REFERENCES
Careaga G, Salazar D, Tellez S, Sanchez O, Borrayo G, Argüero R. ClinicalImpact of Histidine-Ketoglutarato-Tryptophan (HTK) Cardioplegic Solution onthe Perioperative Period in Open Heart Surgery Patients. Archives of MedicalReserch 2001;32: 296-9.
Hachida M, Ookaado A, Nonoyama M, Koyanagi H. Effect of HTK solution formyocadial preservation. J Cardiovasc Surg 1996;37:269-74.
Hachida M, Nonoyama M, Bonkohara M, et al. Clinical assessment of prolongedmyocardial preservation for patients with a severely dilated heart. Ann ThoracSurg 1997;64:59-63.
Sunderdiek U, Feindt P, Gams E. Aortocoronary bypass grafting: a comparationof HTK cardioplegia vs. intermittent aortic cross-clamping. Eur J Cardiovasc Surg2000;18:393-9.
Schaper J, Scheld H, Schmidt U, Hehrlein F. Ultrastructural study comparing theefficacy of five different methods of intraoperative myocardial protection in thehuman heart. J Thorac Cardiovasc Surg1986;92;47-55.
Calderón-Colmenero J, Ramírez MS, Cervantes SJ. Métodos de estratificación deriesgo en la cirugía de cardiopatías congénitas. Arch Cardiol Mex 2008;78: 60-7.
Reichenspurner H, Russ C, Uberfuhr P, et al. Myocardial preservation using HTKsolution for heart transplantation. A multicenter study. Eur J Cardiothorac Surg1993; 7:414-9.
Ackermann J, Gross W, Mory M, Schaefer M, Gebhard M. Celsior versus Custodiol:Early postischemic recovery after cardioplegia and ischemic at 5 oC . AnnThorac Surg 2002;74:522-9.
Argüero-Sanchez R, Mancilla-Olivarez A, Rosales M. Hallazgos estructurales durantela preservación miocárdica con solución de HTK. Cir Ciruj 2004;72:312-35.
Arslan A, Sezgin A, Gultekin B, et al. Low-dose Histidine-Triptophan-Ketoglutamatesolution for myocardial protection. Trasp proc 2005;37:3219-22.
Preusse CJ,Winter J, Schulte D, Bircks W. Energy demand of cardioplegicallyperfused human hearts. J Cardiovasc Surgery 1985:26;558-63.
Kotani Y, Tweddel J, Gruber P, et al. Current Cardioplegia practice in pediatriccardiac surgery: A North American Multiinstitucional Survey. Ann Thorac Surg2013:96:923-9.
Stammers AH, Tesdahl EA, Mongero LB, Stasko AJ, Weinstein S. Does the typeof cardioplegic technique influence hemodilution and transfusion requirements inadult patients undergoing cardiac surgery? J Extra Corpor Technol 2017;49:231-40.
Liu J, Feng Z, Zhao J, Li B, Long C. The myocardial protection of HTK cardioplegicsolution on the long-term ischemic period in pediatric heart surgery. ASAIOJournal 2008;54:470-3.
Elderman JB, Seco M, Dunne B, et al. Custodiol myocardial protection and preservation:a systemic review. Ann Cardiothorac Surg 2013;2:717-28.
Full text